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Ib or Not IIb
s There a Place for Pre-Hospital
irofiban in ST-Segment Elevation
yocardial Infarction Patients?*
on Waksman, MD
ashington, DC
he quest for early and optimal pharmacology therapy for
atients with ST-segment elevation myocardial infarction
STEMI) who are undergoing primary percutaneous coro-
ary intervention (pPCI) is ongoing. The superiority of
PCI over facilitated medical therapy with thrombolytic
gents has been well established for patients presenting with
TEMI (1). Door-to-balloon time has been detected as the
ivotal predictor of survival improvement (2); however, the
verage door-to-balloon time for U.S. patients requiring
ospital transfer to pPCI often exceeds 120 min, which is
uch longer than the 90-min target for optimal pPCI
utcomes. Efforts are therefore targeted to shorten door-to-
alloon times and to find the optimal medical therapy to
estore blood flow to the infarcted artery during the time of
TEMI diagnosis to presentation in the catheterization
aboratory. Although glycoprotein (GP) IIb/IIIa inhibitors
ave proven to be beneficial in reducing clinical events when
iven to STEMI patients in the catheterization laboratory
3), pre-treatment with GP IIb/IIIa inhibitors prior to
rrival in the catheterization laboratory has failed to dem-
nstrate clinical benefit in clinical randomized trials.
See page 2446
The initial report from the On-TIME 2 (Ongoing
irofiban In Myocardial infarction Evaluation) trial was
hat high-bolus dose (HBD) tirofiban, when given in the
mbulance to STEMI patients who were to undergo pPCI,
esulted in an improvement in ST-segment resolution,
hich is defined as a surrogate marker for myocardial
erfusion and an indicator of improved clinical outcome (4).
he trial did not, however, have sufficient power to detect
he impact on mortality at 30 days. The On-TIME 2
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Washington Hospital Center, Washington, DC. Dr. Waksman hasa
eceived a research grant from Schering Plough, and is on the Speakers Bureau of The
edicines Company.nvestigators therefore designed a pre-specified pooled anal-
sis of the placebo-controlled study phase and the open-
abel study phase and reported that in the ambulance, early
dministration of HBD tirofiban for patients with STEMI
esults in a reduction of major adverse cardiac events
MACEs) at 30 days and a trend toward reduction in
ortality at 1 year, without a clinical difference in the
leeding rate (5). Based on these findings, the investigators
oncluded that early, pre-hospital initiation of HBD tirofi-
an, in addition to high-dose clopidogrel, improves the
linical outcome after pPCI in STEMI patients.
There are several deficiencies in this analysis that call for
aution when interpreting the trial results. Although pre-
pecified, this analysis pooled data from 2 phases with
ifferent study designs; the first phase was an open-label
tudy, which is subject to inherent limitations, whereas the
linded phase was underpowered and failed to demonstrate
ny clinical benefit of HBD tirofiban over the placebo when
nalyzed alone. Even when the 2 study phases are com-
ined, the power is suboptimal at 70%. The differences in
rial design may also have affected the differences in the
ail-out use of tirofiban, which was more often used in the
pen-label phase compared with the double-blind study
hase (42% vs. 29%). Further, the clinical benefit conclu-
ions were, in part, drawn from the decrease in MACEs at
0 days, with MACEs driven primarily by urgent target
essel revascularization (TVR). The authors allude to this
VR decrease as being an effect of early stent thrombosis
eduction by the HBD tirofiban; however, the rates of stent
hrombosis were not disclosed in their report. Notably, there
as only a higher rate of urgent TVR in the open-label
hase, which was not replicated in the larger, blinded phase.
herefore, the results of this study are not definitive and
hould be viewed only as hypothesis generating.
Nevertheless, the results fromOn-TIME 2 trial raise several
mportant issues: 1) the value of early pharmacological therapy
n patients presenting with STEMI; 2) the role of HBD
irofiban in this pre-treatment; and 3) will the new emerging
ntiplatelet agents change the paradigm of using GP IIb/IIIa
nhibitors either pre-hospital or intraprocedurally?
rug-to-Balloon Time: The Earlier the Better
lthough the expression “the earlier the better” refers
ainly to mechanical reperfusion of the infarcted artery,
fforts are now aimed at determining how STEMI patients
an undergo early anticoagulation safely and what pharma-
otherapy is optimal for these patients. So far, facilitated
CI has, for the most part, failed across trials to demon-
trate clinical benefit and was usually associated with an
ncrease in bleeding (2,6,7). It is possible that both the
ptimal regimen and time of administration are critical to
he success of pre-hospital pharmacological intervention
nd facilitated PCI may work under specific conditions. In
he On-TIME 2 trial, the median duration of treatment to
ngiography with tirofiban or placebo/no tirofiban was 55
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June 1, 2010:2456–8 Pre-Hospital Tirofiban in STEMI Patientsin. The transfer time is geography dependent, and early
nticoagulation could play a larger role for patients with
onger transport times to a catheterization laboratory that
erforms pPCI in rural areas. An important consideration
ith early anticoagulation is the accuracy in diagnosing
TEMI in the ambulance. In the On-TIME 2 trial,
alse-positive STEMI was diagnosed in 5.8% of patients.
his rate is acceptable but can be even lower with the
issemination of telemedicine, including the on-line trans-
ission of electrocardiograms via smartphone to an experi-
nced cardiologist who can administer medical therapy in
he field.
An interesting observation from the study was the sex
isparity in regard to the efficacy of the drug, which was
ound to be more efficacious in men. This can be explained
y a difference in ischemic time, which was significantly
onger for women and which also emphasizes the impor-
ance of minimizing the ischemic time with early reperfu-
ion and its impact on outcome.
s There a Role for HBD Tirofiban in
re-Treatment of Patients With STEMI?
tandard antiplatelet therapy for today’s STEMI patient is
spirin and a 600-mg loading dose of clopidogrel. The
uestion is whether HBD tirofiban adds any benefit to the
lopidogrel pre-load. Proponents of HBD tirofiban argue
hat it takes at least 2 h to obtain effective platelet inhibition
ith a 600-mg loading dose of clopidogrel compared with
he immediate effect seen with HBD tirofiban. In addition,
BD tirofiban will inhibit platelet function for clopidogrel
onresponders, and, when administered early, it may help to
yse fresh thrombi (4). Nevertheless, in the On-TIME 2
rial, pretreatment with HBD tirofiban was not associated
ith statistically higher rates of Thrombolysis In Myocar-
ial Infarction (TIMI) flow grade 3 or less distal remobili-
ation than in the control group. Thus, the key explanation
or MACE reduction, according to the investigators, is
mproved ST-segment resolution both before and after PCI.
Findings from the On-TIME 2 pooled data analysis are
ot consistent with those of similar trials. In the AGIR-2
Comparison of the Pre-hospital or Cath-lab Administra-
ion of High Doses Tirofiban in Patients Undergoing
rimary Angioplasty) study, 320 STEMI patients within
h of symptom onset were randomized to HBD tirofiban
nfusion in the ambulance or in the catheterization labora-
ory. All patients also received a pre-hospital loading dose of
lopidogrel, aspirin, and heparin. In the pre-hospital group,
irofiban was administered 48 min earlier than in the
atheterization laboratory group. However, results showed
o difference in TIMI III flow at initial angiography (the
rimary end point). There was also no difference in ST-
egment resolution or peak levels of cardiac enzymes.
lthough not powered for clinical events, these data actually
rended toward a worse effect in the pre-hospital group (8). IFurther, in the FINESSE (Facilitated INtervention with
nhanced reperfusion Speed to Stop Events) trial, which
xamined facilitated PCI with early abciximab plus a one-
alf dose of the thrombolytic drug reteplase or with early
bciximab alone, early reperfusion did not translate into any
mprovements in the primary end point (composite of
ll-cause death, ventricular fibrillation, cardiogenic shock,
nd congestive heart failure) or other clinical outcomes at
0 days (9). The difference in clinical outcome in the
n-TIME 2 trial could be explained by the time interval
rom symptom onset to drug administration, which was
horter in On-TIME 2, and the fact that the control was
lacebo and not an active comparator as it was in similar
rials. The lack of difference in bleeding rates between the
reatment groups in On-TIME 2 can be explained by the
se of low-dose heparin and/or an increase in the use of
losure devices. Additionally, this could be a result of the
evel of the anticoagulation efficacy, which does not follow
he usual pattern of a bleeding tax for efficacy gain.
Perhaps the most reassuring finding from On-TIME 2 was
hat even with a 600-mg clopidogrel loading dose, the GP
Ib/IIIa inhibitor showed a potential benefit without a signif-
cant increase in bleeding; however, given the deficiencies of
he study and the lack of clear clinical benefit, these results are
ot sufficient to change guidelines or routine practice.
re-Hospital Antiplatelet Therapy for
TEMI Patients: One Drug Does Not Fit All
he use of GP IIb/IIIa inhibitors for STEMI patients
ontinues to be challenged with the introduction of emerg-
ng antiplatelet therapy agents such as prasugrel and ticagre-
or, which offer rapid onset with more reliable and more
otent platelet inhibition compared with clopidogrel. Ad-
itionally, both have been shown to reduce clinical events,
ncluding stent thrombosis rates, compared with clopi-
ogrel. Administration of prasugrel must await an angio-
ram; however, ticagrelor, with its short half-life, can be
dministered in the ambulance and can eliminate the risk of
leeding on cessation for patients who require urgent
oronary artery bypass graft surgery. The question is
hether new antiplatelet therapies, which have rapid onsets
nd are easy to administer, will substitute the need for
pstream GP IIb/IIIa inhibitor use pre-hospital or perhaps
n the catheterization laboratory. Meanwhile, the use of GP
Ib/IIIa inhibitors for STEMI patients with ticagrelor and
rasugrel of nearly 40% in PLATO (A Study of Platelet
nhibition and Patient Outcomes) (10) to up to 60% in
RITON–TIMI 38 (Trial to Assess Improvement in Ther-
peutic Outcomes by Optimizing Platelet Inhibition with
rasugrel–Thrombolysis in Myocardial Infarction 38) sug-
ests that interventional cardiologists are still comfortable
ith the use of GP IIb/IIIa inhibitors in combination with
he new antiplatelet agents in high-risk STEMI patients.
nterestingly, in TRITON–TIMI 38, the use of GP IIb/
IIa inhibitors did not improve efficacy nor was it associated
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ORIZONS-AMI (Harmonizing Outcomes with Revas-
ularIZatiON and Stents in Acute Myocardial Infarction)
12,13) was the first study to demonstrate a reduction in
leeding and mortality in the bivalirudin without GP
Ib/IIIa inhibitor arm compared with the heparin plus GP
Ib/IIIa inhibitor arm. This arm, however, was associated
ith higher rates of stent thrombosis in the first 24 h after
he pPCI.
Although early pharmacologic intervention for STEMI
atients is warranted and has the potential to expedite
eperfusion of the infarcted vessel prior to arrival at the
atheterization laboratory, the added value of GP IIb/IIIa
nhibitors pre-hospital and/or in the catheterization labora-
ory remains in question in the era of the new, rapid-onset,
otent antiplatelet agents and should be subjected to well-
owered, prospective, randomized clinical trials.
eprint requests and correspondence: Dr. Ron Waksman,
ashington Hospital Center, 110 Irving Street, NW, Suite 4B-1,
ashington, DC 20010. E-mail: ron.waksman@medstar.net.
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